

## PRODUCT INFORMATION

<b>Tag</b>	C-Flag Tag
<b>Target</b>	CLDN18.2
<b>Synonyms</b>	Claudin 18.2
<b>Description</b>	Human Full length Claudin 18.2 Protein-VLP
<b>Delivery</b>	In Stock
<b>Uniprot ID</b>	P56856-2
<b>Expression Host</b>	HEK293
<b>Protein Families</b>	Transmembrane
<b>Protein Pathways</b>	Cell adhesion molecules (CAMs), Leukocyte transendothelial migration, Tight junction
<b>Molecular Weight</b>	The Human CLDN18.2 Protein has a predicted MW of 29 kDa. Due to PTM, the actual MW on SDS-PAGE gel is around 50kDa.
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Storage&amp;Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Background</b>	The protein encodes a member of the claudin family. Claudins are integral membrane proteins and components of tight junction strands. Tight junction strands serve as a physical barrier to prevent solutes and water from passing freely through the paracellular space between epithelial or endothelial cell sheets, and also play critical roles in maintaining cell polarity and signal transductions. This gene is upregulated in patients with ulcerative colitis and highly overexpressed in infiltrating ductal adenocarcinomas. PKC/MAPK/AP-1 (protein kinase C/mitogen-activated protein kinase/activator protein-1) dependent pathway regulates the expression of this gene in gastric cells. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jun 2010]
<b>Usage</b>	Research use only
<b>Conjugate</b>	Unconjugated



## ELISA assay to evaluate CLDN18.2 VLP

0.5 $\mu$ g Human CLDN18.2 VLP per well




Figure1. ELISA plates were pre-coated with 0.5 $\mu$ g/per well purified human CLDN18.2 VLP. Serial diluted Anti-CLDN18.2 monoclonal antibody (Zolbetuximab biosimilar; IMAB362) solutions were added, washed, and incubated with secondary antibody before ELISA reading. From above data, the EC<sub>50</sub> for IMAB362 binding with CLDN18.2 VLP is 15.37ng/ml.




Figure2. FACS analysis of CLDN18.2 VLP

- A. Negative Control 1: CLDN18.2 VLP were stained only with Goat anti-human IgG Fc-PE secondary antibody.  
 B. Negative Control 2: Control VLP were stained with anti-CLDN18.2 antibody (Zolbetuximab biosimilar; IMAB362) at 1 $\mu$ g/mL, followed by Goat anti-human IgG Fc-PE secondary antibody.  
 C. Negative Control 3: CLDN18.2 VLP were stained with anti-BCMA antibody [an irrelevant antibody] at 1 $\mu$ g/mL, followed by Goat anti-human IgG Fc-PE secondary antibody.  
 D. CLDN18.2 VLP were stained with anti-CLDN18.2 antibody [Zolbetuximab biosimilar; IMAB362] at 1 $\mu$ g/mL, followed by Goat anti-human IgG Fc-PE secondary antibody.

